<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138084</url>
  </required_header>
  <id_info>
    <org_study_id>206282</org_study_id>
    <secondary_id>AI438-041</secondary_id>
    <nct_id>NCT02138084</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction (DDI) Rifabutin</brief_title>
  <official_title>Pharmacokinetic Interaction Study to Evaluate the Pharmacokinetic Effect of Rifabutin on BMS-626529, the Active Moiety of BMS-663068, With and Without Ritonavir in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide dosing recommendations for the coadministration of
      BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for
      prescribing information purposes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2014</start_date>
  <completion_date type="Actual">July 24, 2014</completion_date>
  <primary_completion_date type="Actual">July 24, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours after dosing (C12) of BMS-626529</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-626529 (predose)</measure>
    <time_frame>Day 2 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability include incidence of adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead electrocardiograms (ECGs)</measure>
    <time_frame>Up to Day 30 after discontinuation of dose (approximately 45 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BMS-663068 + Rifabutin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: BMS-663068 tablet by mouth as specified
Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: BMS-663068 tablet by mouth as specified
Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Cohort 1: BMS-663068 + Rifabutin</arm_group_label>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin</description>
    <arm_group_label>Cohort 1: BMS-663068 + Rifabutin</arm_group_label>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir</description>
    <arm_group_label>Cohort 2: BMS-663068 + Rifabutin + Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          1. Signed Written Informed Consent

             a) Signed written informed consent must be obtained from the subjects in accordance
             with requirements of the study center's Institutional Review Board (IRB) or
             Independent Ethics Committee (IEC) before the initiation of any protocol-required
             procedures

          2. Target Population

               -  a) Healthy subjects as determined by no clinically significant deviation from
                  normal in medical history, physical examination findings, 12-lead ECG
                  measurements, and clinical laboratory test results

               -  b) Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive BMI = weight
                  (kg)/[height (m)]2

               -  c) Subject Reenrollment: This study permits the reenrollment of a subject that
                  has discontinued the study as a pretreatment failure (ie, subject has not been
                  randomized/has not been dosed). If reenrolled, the subject must be reconsented

          3. Age and Reproductive Status

               -  a) Men and women, ages 18 to 50 years, inclusive

               -  b) Women of childbearing potential (WOCBP) must have a negative serum or urine
                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human
                  chorionic gonadotropin) within 24 hours prior to the start of study drug

               -  c) Women must not be breastfeeding

               -  d) WOCBP must agree to follow instructions for method(s) of contraception for the
                  duration of treatment plus 5 half-lives of Rifabutin (13 days) plus 30 days
                  (duration of ovulatory cycle) for a total of 43 days posttreatment completion

               -  e) Men who are sexually active with WOCBP must agree to follow instructions for
                  method(s) of contraception for the duration of treatment plus 5 half-lives of
                  Rifabutin (13 days) plus 90 days (duration of sperm turnover) for a total of 103
                  days posttreatment completion

        Exclusion Criteria:

        Medical History and Concurrent Diseases

          -  a) Any significant acute or chronic medical illness as determined by the Investigator.

          -  b) Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  c) Any major surgery within 4 weeks of study drug administration

          -  d) Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  e) Intractable diarrhea (â‰¥6 loose stools per day for at least 7 consecutive days)
             within 30 days prior to the first dose of study drug

          -  f) History of acute or chronic pancreatitis

          -  g) History of active or latent tuberculosis or any recent exposure to someone with
             tuberculosis

          -  h) History of uveitis and/or current eye or vision problems with the exception of
             corrective lenses

          -  i) Contact lens use during study drug administration or the need for contact lenses
             during study drug administration

          -  j) Donation of blood to a blood bank or in a clinical study (except screening visit)
             within 4 weeks of study drug administration (within 2 weeks for plasma donation only)

          -  k) Blood transfusion within 4 weeks of study drug administration.

          -  l) History of any hemolytic disorders, including drug-induced hemolysis.

          -  m) Inability to tolerate oral medication

          -  n) Inability to be venipunctured and/or tolerate venous access

          -  o) Recent (within 6 months of study drug administration) history of smoking or current
             smokers

          -  p) Recent (within 6 months of study drug administration) drug or alcohol abuse as
             defined in Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM
             IV), Diagnostic Criteria for Drug and Alcohol Abuse

          -  q) Any other sound medical, psychiatric, and/or social reason as determined by the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

